Literature DB >> 14561794

Early malignant progression of hereditary medullary thyroid cancer.

Andreas Machens1, Patricia Niccoli-Sire, Josef Hoegel, Karin Frank-Raue, Theo J van Vroonhoven, Hans-Dietrich Roeher, Robert A Wahl, Peter Lamesch, Friedhelm Raue, Bernard Conte-Devolx, Henning Dralle.   

Abstract

BACKGROUND: An age-related progression from C-cell hyperplasia to medullary thyroid carcinoma is associated with various germ-line mutations in the rearranged during transfection (RET) proto-oncogene that could be used to identify the optimal time for prophylactic surgery.
METHODS: In this European multicenter study conducted from July 1993 to February 2001, we enrolled patients who had a RET point mutation in the germ line, were 20 years of age or younger, were asymptomatic, and had undergone total thyroidectomy after confirmation of the RET mutation. Exclusion criteria were medullary thyroid carcinomas of more than 10 mm in greatest dimension and distant metastasis.
RESULTS: Altogether, 207 patients from 145 families were identified. There was a significant age-related progression from C-cell hyperplasia to medullary thyroid carcinoma and, ultimately, nodal metastasis in patients whose RET mutations were grouped according to the extracellular- and intracellular-domain codons affected and in those with the codon 634 genotype. No lymph-node metastases were noted in patients younger than 14 years of age. The age-related penetrance was unaffected by the type of amino acid substitution encoded by the various codon 634 mutations. The codon-specific differences in the age at presentation of cancer and the familial rates of concomitant adrenal and parathyroid involvement suggest that the risk of progression was based on the transforming potential of the individual RET mutation.
CONCLUSIONS: These data provide initial guidelines for the timing of prophylactic thyroidectomy in asymptomatic carriers of RET gene mutations. Copyright 2003 Massachusetts Medical Society

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14561794     DOI: 10.1056/NEJMoa012915

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  84 in total

1.  Multiple endocrine neoplasia type 2B with a RET proto-oncogene A883F mutation displays a more indolent form of medullary thyroid carcinoma compared with a RET M918T mutation.

Authors:  Sina Jasim; Anita K Ying; Steven G Waguespack; Thereasa A Rich; Elizabeth G Grubbs; Camilo Jimenez; Mimi I Hu; Gilbert Cote; Mouhammed Amir Habra
Journal:  Thyroid       Date:  2010-12-27       Impact factor: 6.568

Review 2.  Medullary thyroid cancer: monitoring and therapy.

Authors:  Douglas W Ball
Journal:  Endocrinol Metab Clin North Am       Date:  2007-09       Impact factor: 4.741

Review 3.  Surgical management of medullary thyroid carcinoma.

Authors:  Agathoklis Konstantinidis; Michael Stang; Sanziana A Roman; Julie Ann Sosa
Journal:  Updates Surg       Date:  2017-04-13

4.  Sequence variant in the intron 10 of the RET oncogene in a patient with microfollicular thyroid carcinoma with medullar differentiation: implications for newly generated chi-like sequence.

Authors:  Emilija Veljkovic; Radan Dzodic; Gorana Neskovic; Boban Stanojevic; Zorka Milovanovic; Miroslav Opric; Bogomir Dimitrijevic
Journal:  Med Oncol       Date:  2004       Impact factor: 3.064

Review 5.  [Hereditary thyroid cancer].

Authors:  H Dralle; A Machens; K Lorenz
Journal:  Chirurg       Date:  2008-11       Impact factor: 0.955

Review 6.  German Association of Endocrine Surgeons practice guideline for the surgical management of malignant thyroid tumors.

Authors:  Henning Dralle; Thomas J Musholt; Jochen Schabram; Thomas Steinmüller; Andreja Frilling; Dietmar Simon; Peter E Goretzki; Bruno Niederle; Christian Scheuba; Thomas Clerici; Michael Hermann; Jochen Kußmann; Kerstin Lorenz; Christoph Nies; Peter Schabram; Arnold Trupka; Andreas Zielke; Wolfram Karges; Markus Luster; Kurt W Schmid; Dirk Vordermark; Hans-Joachim Schmoll; Reinhard Mühlenberg; Otmar Schober; Harald Rimmele; Andreas Machens
Journal:  Langenbecks Arch Surg       Date:  2013-03-03       Impact factor: 3.445

7.  Pathogenicity of DNA variants and double mutations in multiple endocrine neoplasia type 2 and von Hippel-Lindau syndrome.

Authors:  Zoran Erlic; Michael M Hoffmann; Maren Sullivan; Gerlind Franke; Mariola Peczkowska; Igor Harsch; Matthias Schott; Helmut E Gabbert; Matti Valimäki; Simon F Preuss; Kornelia Hasse-Lazar; Dariusz Waligorski; Mercedes Robledo; Andrzej Januszewicz; Charis Eng; Hartmut P H Neumann
Journal:  J Clin Endocrinol Metab       Date:  2009-11-11       Impact factor: 5.958

8.  [Surgery of thyroid carcinoma].

Authors:  H Dralle; K Lorenz; A Machens
Journal:  Chirurg       Date:  2009-11       Impact factor: 0.955

Review 9.  Update multiple endocrine neoplasia type 2.

Authors:  Friedhelm Raue; Karin Frank-Raue
Journal:  Fam Cancer       Date:  2010-09       Impact factor: 2.375

10.  Long-Term Oncologic Outcomes After Curative Resection of Familial Medullary Thyroid Carcinoma.

Authors:  Philip M Spanheimer; Ian Ganly; Joanne Chou; Marinela Capanu; Ronald A Ghossein; R Michael Tuttle; Richard J Wong; Ashok R Shaha; Brian R Untch
Journal:  Ann Surg Oncol       Date:  2019-09-23       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.